A treatment strategy for KRAS-driven tumors
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SHP2 activation enables resistance mechanisms to MEK inhibitor therapy and enhances expression of signaling upstream from KRAS.
“In addition, SHP2 activation enables resistance mechanisms to MEK inhibitor therapy and enhances expression of signaling upstream from KRAS21.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [21]
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · see citing works
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works
Self-citationMutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · see citing works
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works
Self-citationSHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320 · see citing works
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266 · see citing works
Dardaei, L., Wang, H. Q., Singh, M., Fordjour, P., Shaw, K. X., Yoda, S., Kerr, G., Yu, K., Liang, J., Cao, Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4497 · Cited by 199 · see citing works
Sticking It to Cancer with Molecular Glue for SHP2
Ran, H., Tsutsumi, R., Araki, T., & Neel, B. G. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.010 · Cited by 93 · see citing works
TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer
Chen, M., Sheng, X., Qin, Y.-Y., Zhu, S., Wu, Q., Jia, L., Meng, N., He, Y., & Yan, G. (2019) · Theranostics · doi:10.7150/thno.30224 · Cited by 42 · see citing works
Singh, R., Goldberg, J., Varghese, A. M., Yu, K. H., Park, W., & O'Reilly, E. M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.003 · Cited by 38 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444 · see citing works
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 224 · see citing works
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 192 · see citing works
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 100 · see citing works
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 87 · see citing works
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72 · see citing works
RAF kinase dimerization: implications for drug discovery and clinical outcomes
Brummer, T., & McInnes, C. (2020) · Oncogene · doi:10.1038/s41388-020-1263-y · Cited by 72 · see citing works
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 54 · see citing works
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48 · see citing works
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 47 · see citing works
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 47 · see citing works
TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer
Chen, M., Sheng, X., Qin, Y.-Y., Zhu, S., Wu, Q., Jia, L., Meng, N., He, Y., & Yan, G. (2019) · Theranostics · doi:10.7150/thno.30224 · Cited by 42 · see citing works
The role of the glutamine transporter ASCT2 in antineoplastic therapy
Teixeira, E., Silva, C., & Martel, F. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04218-6 · Cited by 42 · see citing works
Singh, R., Goldberg, J., Varghese, A. M., Yu, K. H., Park, W., & O'Reilly, E. M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.003 · Cited by 38 · see citing works
A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma
Cimmino, F., Lasorsa, V. A., Vetrella, S., Iolascon, A., & Capasso, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.596191 · Cited by 35 · see citing works
Chen, X., Zou, F., Hu, Z., Du, G., Yu, P., Wang, W., Wang, H., Ye, L., & Tian, J. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115019 · Cited by 20 · see citing works
Setting sail: Maneuvering SHP2 activity and its effects in cancer
Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 8 · see citing works
IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation
Wang, S., Yu, G., Dai, Y., Gan, C., Qiu, S., Zhang, X., Jiang, X., Wei, R., Yang, J., Wu, D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3086 · Cited by 7 · see citing works
Ye, W., Liu, Y., Ren, Q., Liao, T., Chen, Y., Chen, D.-M., Wang, S., Yao, L., Jia, Y., Zhao, C., et al. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2078968 · Cited by 7 · see citing works
Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in PreclinicalIn VivoModels
Weidle, U. H., & Nopora, A. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20265 · Cited by 5 · see citing works
Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 4 · see citing works
Enzyme Is the Name—Adapter Is the Game
Huber, M., & Brummer, T. (2024) · Cells · doi:10.3390/cells13151249 · Cited by 3 · see citing works
Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer
Li, Y., Hu, L., & Xu, C. S. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000808 · Cited by 3 · see citing works
Wang, S., Zhao, X., Dong, J. X., Zhang, J., Wang, Y., Jin, H., Jiang, X., Chen, L., Zhang, M., Ji, L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08477-4 · Cited by 1 · see citing works
BindingDB (2022) · UC San Diego · doi:10.7270/q2t1578s
- Authors
- Mai, T. T., & Lito, P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Lito, Piro
- ORCID
- Lito, Piro
- Venue
- Nature Medicine
- Published
- 2018-07
- Volume
- 24
- Issue
- 7
- Pages
- 902-904
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2810721212
- Cited by
- 24
- References
- 14
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA230745)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS mutation, KRAS amplification, SHP2 inhibition, MEK inhibitors, combination therapy, lung adenocarcinoma, pancreatic ductal adenocarcinoma, gastric cancer, KRAS-driven tumors
- MeSH terms
- Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
